AutoGenomics, Inc. and PGXL Labs Company Profile
AutoGenomics Inc., a privately held company based in Vista, CA, has developed the first automated, microarray-based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed, leading to the era of personalized medicine. www.autogenomics.com
News Articles
Microarray and genomics company AutoGenomics Inc. (Carlsbad, Calif.) refiled for an IPO and hopes to raise up to $65 million. Leerink; Stephens; Mizuho Securities; and Cantor Fitzgerald are underwrite...
Microarray and genomics company AutoGenomics Inc. (Vista, Calif.) amended its IPO and now plans to sell 6 million shares at $9-$11. A $10 price would raise $60 million and value the company at $167.5...
[AutoGenomics] attempts IPO a second time
Molecular diagnostics instrument maker [AutoGenomics Inc.] is making a second attempt to go public on Nasdaq. The company first filed in July 2008 but withdrew the offer last year. This time around Au...
PGXL to Provide Antipsychotic Drug Response Tests
SureGene has chosen PGXL as laboratory provider for its proprietary STA2R genetic panel, which promises to revolutionize the treatment of schizophrenia. “The STA...
SureGene selects PGXL as laboratory provider for STA2R genetic panel
SureGene has chosen PGXL as laboratory provider for its proprietary STA2R genetic panel, which promises to revolutionize the treatment of schizophrenia.
PGXL, SureGene unveil new antipsychotic and antidepressant test
SureGene and PGXL Laboratories have joined forces to launch the SureGene Test for Antipsychotic and Antidepressant Response (STA2R), which is a pharmacogenetic test containing genetic markers for effe...
AutoGenomics : IPO for $65 million
AutoGenomics Inc. is again looking to go public, filing plans for an estimated initial public offering of up to $65 million in common stock. The company plans to use its IPO proceeds to expand its sal...
Diagnostics Instrument Maker AutoGenomics Files Again for IPO
AutoGenomics, a Vista, CA-based company that specializes in molecular diagnostics systems, has filed for a $65 million Initial Public Offering (IPO), according to a recent regulatory filing. The compa...
Drugs and Medications
Sure antiperspirant deodorant unscented [Idelle Labs, Ltd]
Sure Aerosol Antiperspirant Deodorant Unscented
Sure antiperspirant deodorant regular [Idelle Labs, Ltd]
Sure Aerosol Antiperspirant Deodorant Regular Scent
Ammens medicated powder shower fresh formula [Idelle Labs, Ltd]
Ammens Medicated Powder Shower Fresh Formula
Ammens medicated powder original [Idelle Labs, Ltd]
Ammens Medicated Powder
Brut anti-perspirant and deodorant [Idelle Labs, Ltd]
Brut Anti-perspirant and Deodorant
PubMed Articles
In this paper we describe a statistical analysis of the inter-laboratory data summarized in Rosati et al. (2008) to assess the performance of an analytical method to detect the presence of dust from t...
Virtual Labs in proteomics: New E-learning tools.
Web-based educational resources have gained enormous popularity recently and are increasingly becoming a part of modern educational systems. Virtual Labs are E-learning platforms where learners can ga...
Clinical Trials
Teen-LABS is using standardized techniques to assess the short and longer-term safety and efficacy of bariatric surgery in adolescents compared to adults.
Long-Term Effects of Bariatric Surgery
The primary objective of LABS-2 is to use standardized techniques and measures to assess the longer-term safety and efficacy of bariatric surgery by: 1. comparing post-surgical outcomes...
To determine, in a randomized, parallel open-label fashion, compliance rates between once-daily extended-release divalproex sodium tablets (Depakote-ER®, Abbott Labs) versus multiple-dail...
Longitudinal Assessment of Bariatric Surgery
The goal of the LABS-1 study is to assess the short-term safety of bariatric surgery.
Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers
This trial will be conducted in the United States of America (USA). The aim of this clinical trial is to investigate whether NNC 0070-0002-0349 is safe and well tolerated. Groups...
Companies
AutoGenomics, Inc. and PGXL Labs
AutoGenomics Inc., a privately held company based in Vista, CA, has developed the first automated, microarray-based multiplexing diagnostic platform that can be used to assess dis...
AutoGenomics Inc., a privately held company based in Carlsbad, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures wi...
A privately-owned business located in Louisville, Kentucky, PGXL Laboratories was the first lab in the country CLIA-certified specifically to conduct pharmacogenetic tests. It offers pharmacogenetic t...
AutoGenomics Inc., a privately held company based in Carlsbad, CA, has developed the first automated, microarray based multiplexing diagnostic platforms that can be used to assess disease signatur...
More Information about "AutoGenomics, Inc. and PGXL Labs" on BioPortfolio
We have published hundreds of AutoGenomics, Inc. and PGXL Labs news stories on BioPortfolio along with dozens of AutoGenomics, Inc. and PGXL Labs Clinical Trials and PubMed Articles about AutoGenomics, Inc. and PGXL Labs for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AutoGenomics, Inc. and PGXL Labs Companies in our database. You can also find out about relevant AutoGenomics, Inc. and PGXL Labs Drugs and Medications on this site too.
